Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Royal Philips (Koninklijke Philips N.V., NYSE: PHG) is a health technology company whose news flow centers on diagnostic imaging, ultrasound, image-guided therapy, monitoring, enterprise informatics and personal health. Company announcements frequently highlight AI-enabled systems, new product launches and strategic portfolio moves, giving investors and observers insight into how Philips develops and positions its health technology offerings.
Recent Philips news has featured AI-powered innovations in image-guided therapy and diagnostic imaging, such as LumiGuide 3D Device Guidance for light-based navigation during minimally invasive procedures, DeviceGuide for AI-assisted tracking of heart valve repair devices, and Verida, a detector-based spectral CT system with AI integrated across the imaging chain. The company also reports advances in MRI through its BlueSeal Horizon 3.0T platform and extended partnerships in neuroimaging, such as the integration of Cortechs.ai quantitative analytics into Philips MR workflows.
News items also cover enterprise informatics and cloud-based solutions, including the launch of Philips Management 15, a web-based diagnostic viewer that delivers full radiology capabilities through a browser and interfaces with AI tools and interactive reporting. In addition, Philips communicates on long-term partnerships with health systems, monitoring agreements and large-scale deployments of its Azurion image-guided therapy systems.
Corporate and portfolio developments appear regularly in the news stream. Examples include the agreement to acquire SpectraWAVE Inc. to expand intravascular imaging and physiology solutions, and the completed carve-out of the Philips Emergency Care business, which now operates as Heartstream under a Philips brand license. Earnings-related releases and Form 6-K summaries provide context on comparable order intake, sales trends, margins, productivity programs and outlook.
Investors and healthcare professionals following PHG news can use this page to track product introductions, AI and imaging milestones, strategic transactions and quarterly performance updates that shape Philips’ role in global health technology.
Philips (NYSE: PHG) expanded its digital pathology portfolio on March 11, 2026 with Philips IntelliSite Pathology Solution on HealthSuite, a fully cloud-enabled offering powered by Amazon Web Services to help labs scale digital workflows, store and review high-resolution pathology images, and enable remote collaboration and AI integration.
The solution builds on Philips’ FDA-cleared scanners, existing installed base and HealthSuite Integrated Diagnostics portfolio; availability and AI features are limited in certain jurisdictions, including the USA.
Philips (NYSE: PHG) showcased platform-based connected care intelligence at HIMSS26 on March 10, 2026, focusing on enterprise patient monitoring and Integrated Diagnostics.
Philips emphasized interoperable, AI-enabled platforms that link monitoring, imaging, EMR and third-party systems to create longitudinal patient visibility, reduce fragmentation, and accelerate diagnostic insight; the Future Health Index 2025 found 77% of clinicians lost time due to inaccessible patient data.
Philips Sonicare (NYSE: PHG) on March 5, 2026 unveiled two new electric toothbrush ranges, a Next-Generation Sonicare drivetrain across 5700–7300 Series, a refreshed "Feel the Care" brand platform, and sustainability upgrades to brush heads and packaging.
Key details: new motor delivering up to 62,000 bristle movements per minute, multiple MSRP tiers ($59.99–$199.99), staged retail rollouts (January–February 2026), 21-day battery life on select models, and brush heads now 70% bio-based with 100% recyclable packaging.
Philips (NYSE:PHG) introduced Rembra on March 4, 2026 — a CE-marked, 510(k)-pending CT system built for acute and high-demand imaging.
Key specs: up to 106 images/sec, throughput up to 270 patients/day, largest-in-class 85 cm bore, NanoPanel Precise XD detector with 23 lp/cm resolution and 0.25 mm detail, and a Tube for Life program covering tube replacement up to 10 years.
Royal Philips (NYSE: PHG) published its Annual Report 2025 on February 19, 2026. The report has been filed with the Netherlands Authority for the Financial Markets in ESEF and is expected to be filed on Form 20-F with the SEC later today.
The Annual Report 2025 will be on the agenda of the Annual General Meeting of Shareholders on May 8, 2026. The report (ESEF and Form 20-F) is available at www.results.philips.com, and printed copies can be requested via annual.report@philips.com. Investor and media contacts are provided for further information.
Philips (NYSE: PHG) announced availability of the InkSpace Imaging Snuggle™ pediatric body array coil for Philips 3.0T MRI systems on February 12, 2026. The coil received FDA 510(k) clearance and is designed to improve pediatric comfort with a soft, flexible, blanket-like form while enabling high-density, high-resolution imaging.
The device aims to reduce repeat scans and speed setup, improving technologist workflow; it is available in the United States now, with broader regional rollout planned.
Philips (NYSE:PHG) reported full-year 2025 group sales of EUR 17.8 billion and comparable sales growth of 2%. Adjusted EBITA margin rose 80 basis points to 12.3% and income from operations was EUR 1,424 million. Free cash flow was EUR 512 million (includes EUR 1,025 million recall-related settlements).
Q4 showed acceleration: comparable sales +7%, Adjusted EBITA 15.1% and free cash flow EUR 1,200 million. Philips delivered EUR 2.5 billion productivity target and set 2026-2028 targets including mid-single-digit comparable sales CAGR, mid-teens Adjusted EBITA margin by 2028, and EUR 4.5-5.0 billion cumulative FCF.
Royal Philips (NYSE: PHG) proposed re-appointment of Roy Jakobs as President & CEO and Board of Management member, to be voted at the AGM on May 8, 2026. The Supervisory Board cited progress since 2022, EUR 2.5 billion productivity savings, restored growth, improved margins, positive cash generation and a stronger balance sheet.
Jakobs will present Philips’ plan to drive profitable growth at the company’s Capital Markets Day later today.
Philips (NYSE:PHG) received Frost & Sullivan's 2025 Global Enabling Technology Leadership Recognition for Digital Pathology–Healthcare Informatics on Jan 29, 2026.
The award cites Philips' integrated digital pathology portfolio, FDA 510(k) clearance for primary diagnosis, >3,500 pathologists across 40+ countries, and >38 million slides scanned globally.
Royal Philips (NYSE: PHG) was named a Clarivate Top 100 Global Innovator for 2026 on January 21, 2026, its 13th consecutive year on the list and the highest-ranking medical technology company included.
Recognition highlights Philips' long-term innovation focus, supported by more than EUR 1.7 billion in annual R&D investment (about 9% of sales). Recent innovations cited include the Philips Verida detector-based spectral CT, helium-free MRI magnet technology with >2,000 installations and ~6 million liters of helium saved, the Flash 5100 point-of-care ultrasound, a next-generation web diagnostic viewer, and AI-enabled consumer care products.